Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Purinergic Receptor (Purinoceptor) Antagonists: Overview
Membrane receptors that are activated by the purine nucleoside adenosine (adenosine receptors) or by purine or pyrimidine nucleotides (P2Y and P2X receptors) transduce extracellular signals to the cytosol. They play important roles in physiology and disease. The G protein-coupled adenosine receptors comprise four subtypes: A1, A2A, A2B, and A3. The G-protein-coupled P2Y receptors are subdivided into eight subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14, while the P2X receptors represent ATP-gated homomeric or heteromeric ion channels consisting of three subunits; the most important subunits are P2X1, P2X2, P2X3, P2X4, and P2X7. Purinergic receptors play important roles in central nervous system (CNS). These receptors are involved in cellular neuroinflammatory responses that regulate functions of neurons, microglial and astrocytes. Based on their endogenous ligands, purinergic receptors are classified into P1 or adenosine, P2X and P2Y receptors. During brain injury or under pathological conditions, rapid diffusion of extracellular adenosine triphosphate (ATP) or uridine triphosphate (UTP) from the damaged cells, promote microglial activation that result in the changes in expression of several of these receptors in the brain.
'Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape is provided which includes the disease overview and Purinergic Receptor (Purinoceptor) Antagonists treatment guidelines. The assessment part of the report embraces, in depth Purinergic Receptor (Purinoceptor) Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Purinergic Receptor (Purinoceptor) Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Purinergic Receptor (Purinoceptor) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs
Further product details are provided in the report……..
Purinergic Receptor (Purinoceptor) Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Purinergic Receptor (Purinoceptor) Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Purinergic Receptor (Purinoceptor) Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Purinergic Receptor (Purinoceptor) Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinergic Receptor (Purinoceptor) Antagonists drugs.
Purinergic Receptor (Purinoceptor) Antagonists Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Purinergic Receptor (Purinoceptor) Antagonists: Overview
Membrane receptors that are activated by the purine nucleoside adenosine (adenosine receptors) or by purine or pyrimidine nucleotides (P2Y and P2X receptors) transduce extracellular signals to the cytosol. They play important roles in physiology and disease. The G protein-coupled adenosine receptors comprise four subtypes: A1, A2A, A2B, and A3. The G-protein-coupled P2Y receptors are subdivided into eight subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14, while the P2X receptors represent ATP-gated homomeric or heteromeric ion channels consisting of three subunits; the most important subunits are P2X1, P2X2, P2X3, P2X4, and P2X7. Purinergic receptors play important roles in central nervous system (CNS). These receptors are involved in cellular neuroinflammatory responses that regulate functions of neurons, microglial and astrocytes. Based on their endogenous ligands, purinergic receptors are classified into P1 or adenosine, P2X and P2Y receptors. During brain injury or under pathological conditions, rapid diffusion of extracellular adenosine triphosphate (ATP) or uridine triphosphate (UTP) from the damaged cells, promote microglial activation that result in the changes in expression of several of these receptors in the brain.
'Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape is provided which includes the disease overview and Purinergic Receptor (Purinoceptor) Antagonists treatment guidelines. The assessment part of the report embraces, in depth Purinergic Receptor (Purinoceptor) Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Purinergic Receptor (Purinoceptor) Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Purinergic Receptor (Purinoceptor) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Purinergic Receptor (Purinoceptor) Antagonists.
This segment of the Purinergic Receptor (Purinoceptor) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs
- Gefapixant: Merck & Co
- Selatogrel: Idorsia Pharmaceuticals
Further product details are provided in the report……..
Purinergic Receptor (Purinoceptor) Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Purinergic Receptor (Purinoceptor) Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Purinergic Receptor (Purinoceptor) Antagonists
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Purinergic Receptor (Purinoceptor) Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Purinergic Receptor (Purinoceptor) Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinergic Receptor (Purinoceptor) Antagonists drugs.
Purinergic Receptor (Purinoceptor) Antagonists Report Insights
- Purinergic Receptor (Purinoceptor) Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Purinergic Receptor (Purinoceptor) Antagonists drugs?
- How many Purinergic Receptor (Purinoceptor) Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinergic Receptor (Purinoceptor) Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Purinergic Receptor (Purinoceptor) Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Purinergic Receptor (Purinoceptor) Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Incyte Corporation
- Arcus Biosciences
- Corvus Pharmaceuticals
- Idorsia Pharmaceuticals
- Tarus Therapeutics
- Dizal Pharmaceutical
- Corvus Pharmaceuticals
- INCB-106385
- Etrumadenant
- Ciforadenant
- Selatogrel
- TT-4
- TT-10
- DZD-2269
- Ciforadenant
Introduction
Executive Summary
Purinergic Receptor (Purinoceptor) Antagonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Selatogrel: Idorsia Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Etrumadenant: Arcus Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
DZD-2269: Dizal Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Purinergic Receptor (Purinoceptor) Antagonists Key Companies
Purinergic Receptor (Purinoceptor) Antagonists Key Products
Purinergic Receptor (Purinoceptor) Antagonists- Unmet Needs
Purinergic Receptor (Purinoceptor) Antagonists- Market Drivers and Barriers
Appendix
Executive Summary
Purinergic Receptor (Purinoceptor) Antagonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Selatogrel: Idorsia Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Etrumadenant: Arcus Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
DZD-2269: Dizal Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Purinergic Receptor (Purinoceptor) Antagonists Key Companies
Purinergic Receptor (Purinoceptor) Antagonists Key Products
Purinergic Receptor (Purinoceptor) Antagonists- Unmet Needs
Purinergic Receptor (Purinoceptor) Antagonists- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Purinergic Receptor (Purinoceptor) Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Purinergic Receptor (Purinoceptor) Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Purinergic Receptor (Purinoceptor) Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Purinergic Receptor (Purinoceptor) Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
